JAKARTA (BPN/PR) – The increased awareness of preventive healthcare in the health industry has aroused a new habit in society to implement a healthy lifestyle according to their genetics, such in the choice of food, diet pattern, early prevention from the future potential of diseases or any type of sports in accordance to one’s genetic predisposition.
Thus, PT Henindo Technologies Citra Mulia (HENINDO) together with PT Regene Artifisial Inteligen (REGENE) announced the launching of a comprehensive DNA TEST under the brand name of DNAtest.id.
DNAtest.id is a One-Stop-Solution DNA Screening for early preventive health solutions using genetic testing. DNAtest.id covers the Nutrigenomic, Pharmacogenomic, Dermatology, early detection of allergy, immunity, cancer, cardiology, lungs, renal, digestion, liver, and other diseases screening.
“DNA test is an early risk detection on a disease, hence it is very important to be accessed by the public,” said Prof. Dr. dr. Yudi Ahmad Yudianto, SpFM(K), SH, M.K, Indonesian DNA Expert.
DNAtest.id as a domestic product is the most comprehensive genetic test in Indonesia’s existing market. It comprises 3 main products such as DNA Screening, DNA Bloodline, and DNA Private.
DNA Screening is an accurate screening that unveils information in regards one’s genetic predisposition, consisting of 35 cancer traits, 13 hormone traits, and over 180 disease traits along with the nutritional needs with 34 traits including the risk of COVID-19 and its severity of illness from COVID-19 infection based on one’s genetic predisposition.
On the other hand, DNA Bloodline and DNA Private is a DNA test covering paternity and ancestry recognition.
“The difference between Screening DNA and Bloodline or Private DNA is that Screening DNA makes use of one’s DNA Codes while Bloodline DNA and Private DNA only examine a Non-Coded DNA,” said Forensic DNA Expert Putut Tjahjo Widodo, DFM, M.Si, as Henindo Operational Director.
REGENE laboratory implements an international standard with a call rate above 0.99, in addition, REGENE used a Polygenic Risk Score (PRS) to produce the DNA report thus increasing the accuracy by more than 99,98%.
At the launching event, a Talkshow themed “Empowering your life with DNA test” was attended by health industry partners, all other insurance practitioners, technology practitioners,s and venture capital.
“We are very proud to be able to play part in the genetic biotech world to support the acceleration of genomic industry growth in Indonesia and actively open a collaboration whether in the field of research or other commercial aspects,” said REGENE CEO Vichi Lestari.
Since its incorporation in 1996, Henindo has been a long-standing and prominent company engaging in technology and health equipment along with other pharmaceutical products in Indonesia. In the meantime, Henindo has been cooperating with more than 50 hospitals and hundreds of health equipment and pharmaceuticals distributor in Indonesia.
Henindo has been trusted by many international technology counterparts and appointed as principals and distributors in engineering tools and equipment while diversifying its business in the health industry.
REGENE is a genetic biotech start-up founded by Vichi Lestari and Desmond Previn, equipped with an end-to-end platform from the genetic laboratory with genotyping and sequencing capabilities, a genetically based therapeutic center, and a training center for all genomic practitioners along with research team and seasoned technologist.
